Inhibition of xenogeneic GVHD by PEN110 treatment of donor human PBMNCs

• Published in: Transfusion (Philadelphia, Pa.) Vol. 44; no. 2; pp. 282 - 285
• Main Authors: Fast, Loren D., Semple, John W., DiLeone, Gilbert, Kim, Michael, Freedman, John, Chapman, John, Purmal, Andrei
• Format: Journal Article
• Language: English
• Published: Oxford, UK and Malden, USA Blackwell Science Inc 01.02.2004
• Subjects: Animals; Antibodies, Heterophile; Disease Models, Animal; Erythrocyte Transfusion - adverse effects; Graft vs Host Disease - immunology; Graft vs Host Disease - prevention & control; Humans; Leukocytes - immunology; Mice; Mice, SCID; Polyamines - pharmacology
• ISSN: 0041-1132; 1537-2995
• DOI: 10.1111/j.1537-2995.2004.00639.x

BACKGROUND: Development and characterization of methods for preventing transfusion‐associated GVHD have utilized in vitro studies with human WBCs and in vivo studies in animal models. The limitation of these assays is that the in vivo GVHD response of treated human WBCs has not been tested directly. STUDY DESIGN AND METHODS: PBMNCs isolated from nonleukoreduced RBC units exposed to gamma irradiation, treated with PEN110 or PBS, were tested for their ability to induce xenogeneic GVHD when injected into severe combined immunodeficient (SCID) mice. RESULTS: These studies showed that the SCID mice injected with PBS‐treated PBMNCs developed serum levels of human immunoglobulin that were followed by weight loss and display of ruffled fur characteristic of xenogeneic GVHD in these mice. In contrast, SCID mice injected with PEN110‐treated or gamma‐irradiated PBMNCs did not exhibit any of these responses. CONCLUSIONS: In these studies PEN110 treatment and gamma irradiation were equally effective at preventing in vivo GVHD responses when the treated cells were injected into SCID recipients. These results are consistent with previous results obtained when these two treatment methods were compared with in vitro studies with PBMNCs and in vivo studies in mouse models.